Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target
Lantheus and Point Biopharma shares drop on prostate cancer treatment data
Eli Lilly extends tender offer to buy Point Biopharma to Dec. 15
Eli Lilly extends tender offer to buy Point Biopharma after low participation
Eli Lilly to Buy Point Biopharma for $1.4 Billion
Eli Lilly to buy cancer-focused Point Biopharma for $1.4 billion
Point Biopharma Global's stock jumps more than 80% after Lilly merger deal